Please login to the form below

Not currently logged in
Email:
Password:

US market

This page shows the latest US market news and features for those working in and with pharma, biotech and healthcare.

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Moreover, two-thirds of Humira’s $18bn net revenues last year were made in the US market. ... victory for the company, ceding that market in order to reinforce the greater prize of longer US exclusivity.

Latest news

  • Dermira craters as acne drug fails late-stage test Dermira craters as acne drug fails late-stage test

    Dermira craters as acne drug fails late-stage test. The US biotech lost two-thirds of its share value after the news broke. ... The topical drug, which acts to inhibit sebum production in the skin by blocking acetyl coenzyme-A carboxylase, had been

  • FDA backs earlier use of Lilly’s breast cancer drug Verzenio FDA backs earlier use of Lilly’s breast cancer drug Verzenio

    year and is predicted to become a $6bn product at peak by EvaluatePharma - as well as Novartis’second-to-market CDK4/6 inhibitor Kisqali (ribociclib)). ... Kisqali made $35m in its first few months on the market after launches in the US and Europe in

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    Pfizer’ s leukaemia drug Mylotarg backed for use in EU. The CHMP’s positive opinion could see the drug return to market after almost eight years. ... Mylotarg (gemtuzumab ozogamicin) was the first antibody-drug conjugate to reach the market nearly

  • Bad news for Portola as CHMP considers Factor Xa drugs Bad news for Portola as CHMP considers Factor Xa drugs

    Moreover, the CHMP still have concerns about betrixaban that will continue to delay approval, even though it has already been approved by the US FDA as Bevyxxa. ... according to Lis, who said that verdict is “particularly disappointing”and means that

  • PROSPER data reveal big Xtandi benefit in early-stage prostate cancer PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

    There are currently no approved systemic therapies for patients with non-metastatic CRPC in the US, ”she added. ... The market category will see some significant disruption later this year however when generics of Zytiga reach the big US market.

More from news
Approximately 1 fully matching, plus 794 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    In addition the US stock market excited by the prospect of changes in corporate tax and greater government investment driving growth has risen to new highs. ... 1, 410 (upfront 80). WuXi Biologics and Gloria Pharma (CN). Arcus Biosciences (US).

  • Hacking Innovation Hacking Innovation

    invent an anti-pollution product, but also to prepare and deliver their pitch for how the product could deliver real change should it be chosen to hit the Chinese market. ... He explains: “We look for life-changing creativity that we can put into

  • Deal Watch - May 2017 Deal Watch - May 2017

    For Sawai this acquisition represents an entry into the US market and as such the current facilities and management will be retained. ... Medical devices and diagnostics with sales of $3.7bn. 24, 000. Medtronic (US/IE).

  • Making digital health personal Making digital health personal

    Progress tracking: A case study. This case study looks at a native app developed in the US market for a local pharma client that allows patients to plan their medication schedule;

  • Speaking the language of effective communications Speaking the language of effective communications

    That's the same on both sides of the ocean. In the US we're looking very much to the models in the EU about how market access is working, because ... In the US that's less often the case, unless people work in a global team.

More from intelligence
Approximately 0 fully matching, plus 39 partially matching documents found.

Latest appointments

  • Open Health creates new role Open Health creates new role

    Joining the agency with twenty years’biopharmaceutical industry experience, Jones’expertise lies in market access, therapy launch and patient centric services. ... Creating a unique role within our field of expertise will enable us to offer a market

  • W2O bolsters its commercialisation offering W2O bolsters its commercialisation offering

    W2O bolsters its commercialisation offering. Rita Glaze joins the firm as leader of value, pricing and market access practice. ... Joining the network from Edelman, Glaze previously led the design and implementation of its US market access communications

  • Amra appoints new VP of North American sales Jeremy Edwards Amra appoints new VP of North American sales Jeremy Edwards

    Body composition analysis group, Amra, has made a trio of new-hires to support its growth and expansion of its operations into the US. ... expand the US market.”.

  • Portland Health appoints Alfred Jackson as a partner Portland Health appoints Alfred Jackson as a partner

    He said: “The opportunity to help Portland expand its impressive health footprint to the US market is an incredible opportunity. ... agency experience, senior leadership and strategic relationships across the health and government sectors to deepen our

  • Ron Menezes joins Almirall’s Aqua Pharmaceuticals Ron Menezes joins Almirall’s Aqua Pharmaceuticals

    Sanchiz added: “Almirall continues to consider Aqua as a very important platform in the US market to support existing and new products.”. ... Aqua Pharmaceuticals was acquired by the Spanish group back in 2013 - a deal that was worth around $400m -

More from appointments
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics